Literature DB >> 21597096

Survival from common and rare cancers in Germany in the early 21st century.

E Hiripi1, A Gondos, K Emrich, B Holleczek, A Katalinic, S Luttmann, E Sirri, H Brenner.   

Abstract

BACKGROUND: Until recently, population-based data of cancer survival in Germany mostly relied on one registry covering ∼1 million people (1.3% of the German population). Here, we provide up-to-date cancer survival estimates for Germany based on data from 11 population-based cancer registries, covering 33 million people and compare them to survival estimates from the United States. PATIENTS AND METHODS: Cancer patients diagnosed in 1997-2006 were included. Period analysis was employed to calculate 5-year relative survival for 38 cancers for 2002-2006. German and USA survival rates were compared utilizing the Surveillance, Epidemiology and End Results 13 database.
RESULTS: Five-year relative survival >80% was observed for testicular cancer (93.5%), skin melanoma (89.4%), cancers of the prostate (89.1%) and thyroid (87.8%), Hodgkin's lymphoma (84.5%) and cancers of the breast (83.7%) and endometrium (81.0%), which together account for almost 40% of cases. For the majority of cancers, German survival estimates were close to or below those in the United States. Exceptions with higher survival in Germany were cancers of the stomach, pancreas and kidney and Hodgkin's lymphoma.
CONCLUSIONS: German cancer survival estimates are mostly higher than the 2000-2002 pan-European estimates. Further research is needed to investigate causes responsible for differences between German and USA cancer survival rates.

Entities:  

Mesh:

Year:  2011        PMID: 21597096     DOI: 10.1093/annonc/mdr131

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  28 in total

1.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

2.  Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age.

Authors:  A Stang; L Jansen; B Trabert; C Rusner; A Eberle; A Katalinic; K Emrich; B Holleczek; H Brenner
Journal:  Cancer Epidemiol       Date:  2013-04-23       Impact factor: 2.984

3.  [Combined modality treatment of oesophageal cancer].

Authors:  M Stahl; T Ruhstaller
Journal:  Internist (Berl)       Date:  2014-01       Impact factor: 0.743

4.  Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival.

Authors:  Christian O Jacke; Ute S Albert; Iris Reinhard; Matthias Kalder
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-16       Impact factor: 4.553

5.  Cancer survival in Eastern and Western Germany after the fall of the iron curtain.

Authors:  Lina Jansen; Adam Gondos; Andrea Eberle; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2012-08-22       Impact factor: 8.082

6.  Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage.

Authors:  Tianhui Chen; Lina Jansen; Adam Gondos; Meike Ressing; Bernd Holleczek; Alexander Katalinic; Hermann Brenner
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

Review 7.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Authors:  A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki
Journal:  J Gastrointest Cancer       Date:  2015-09

8.  Survival of patients with oral cavity cancer in Germany.

Authors:  Stefan Listl; Lina Jansen; Albrecht Stenzinger; Kolja Freier; Katharina Emrich; Bernd Holleczek; Alexander Katalinic; Adam Gondos; Hermann Brenner
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

9.  A multisource approach to improving epidemiologic estimates: application to global B-cell malignancies.

Authors:  Meghan E Mitchell; Kimberly Lowe; Jon Fryzek
Journal:  ISRN Oncol       Date:  2012-12-31

10.  Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy.

Authors:  Gisèle Compaci; Manuela Rueter; Sébastien Lamy; Lucie Oberic; Christian Recher; Maryse Lapeyre-Mestre; Guy Laurent; Fabien Despas
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.